Evogene Stock News

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

Medical-grade cannabis developer Canonic Ltd. , and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN ), announced that professor Itamar Grotto will be joining its board of directors . Grotto, f ormer associate director general at the Israeli ministry of health , was responsible for the medicalization reform of cannabis in Israel and oversaw the Israeli medical cannabis agency . He was also the director of Israel''s public health services and a member of the executive board of the WHO , on behalf of the state of … Full story available on Benzinga.com

Computational biology company Evogene Ltd . (NASDAQ: EVGN ) will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022 . On the day of the announcement, the company''s management will host a conference call to discuss the results at 09:00 a.m. EST. Evogene established three unique … Full story available on Benzinga.com

REHOVOT, Israel, Feb. 15, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the full…

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we k

Evogene''s <> unit Canonic said it shipped the first batch of its unique cannabis varieties to Portugal, after receiving export approval by the Israeli Ministry of Health and

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we d

Medical grade cannabis products developer Canonic Ltd., a subsidiary of Evogene Ltd.

Biomica and a subsidiary of Evogene (EVGN) announce that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept ((POC)), Phase I clinical trial

Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.58, giving the company a market cap of $66M. The stock is currently down 1.8% year-to-date, down 68.7% over the past 12 months, and down 68.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 10.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -75.0% The company's stock price performance over the past 12 months lags the peer average by 110.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.60, giving the company a market cap of $67M. The stock is currently down 65.3% year-to-date, down 71.0% over the past 12 months, and down 68.0% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 56.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 395.8% The company's stock price performance over the past 12 months lags the peer average by 396.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Geode Capital Management LLC grew its stake in Evogene Ltd. (NASDAQ:EVGN) by 40.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,731 shares of the biotechnology companys stock after purchasing an additional 7,761 shares during the period. Geode Capital Management LLC [] The post Evogene Ltd. (NASDAQ:EVGN) Shares Acquired by Geode Capital Management LLC appeared first on ETF Daily News .

REHOVOT, Israel, Nov. 30, 2021 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program. In

Zacks Investment Research lowered shares of Evogene (NASDAQ:EVGN) from a hold rating to a sell rating in a research note released on Monday, Zacks.com reports. According to Zacks, Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding []